Navigation Links
Estrogen-Only Therapy May Reduce Breast Cancer Risk
Date:3/7/2012

By Denise Mann
HealthDay Reporter

TUESDAY, March 6 (HealthDay News) -- Some women who take estrogen-only hormone replacement therapy to stave off hot flashes, night sweats and other symptoms of menopause may be at lower risk for developing breast cancer down the road, a news study says.

Hormone replacement therapy (HRT) fell from grace rather dramatically after a large government-run trial, the U.S. Women's Health Initiative, was stopped early in 2002 because HRT was shown to increase the risk of strokes and breast and ovarian cancer. Since that time, however, some subtleties have emerged as researchers parsed the evidence further. For example, short-term use of HRT is now deemed fairly safe for some women who have severe menopausal symptoms.

The new study shows that longer-term use of estrogen-only therapy may actually lower a woman's odds of developing breast cancer. Estrogen-only therapy is reserved for women who have had a hysterectomy; women with an intact uterus who use HRT must take the hormone progestin with estrogen to prevent uterine cancer.

"Women who have had a hysterectomy may be reassured that taking estrogen by itself, short term, to relieve menopausal symptoms will not increase their risk of breast cancer," said study author Garnet Anderson of the Women's Health Initiative Clinical Coordinating Center at the Fred Hutchinson Cancer Research Center in Seattle. Women should not take estrogen to prevent breast cancer, she stressed.

The new findings were published in the March 7 online edition of The Lancet Oncology.

The North American Menopause Society recently released a position statement that backs up these findings. The group said starting combination hormone therapy (both estrogen and progestin) around the time of menopause to treat symptoms and stave off the brittle-bone disease osteoporosis is safe for some women for three to five years. Estrogen alone can be used for longer than the combination HRT, according to the society.

The new study, which was partially funded by drug manufacturer Wyeth, included more than 7,500 women from the Women's Health Initiative who took estrogen for about six years. Roughly five years after stopping treatment, the women were 23 percent less likely to develop breast cancer when compared to their counterparts who never used HRT.

Women in the estrogen group who did develop breast cancer were 63 percent less likely to die from the disease, compared to women who never took it. The lower risk of breast cancer was seen only among women without risk factors for breast cancer, such as a history of benign breast disease or a strong family history of breast cancer, the study showed.

"The story is pretty clear about estrogen plus progestin -- no matter the age of the women, estrogen plus progestin increases [the risk of] breast cancer, heart disease, stroke and blood clots," Anderson said. "These risks outweigh the benefits for all age groups."

Why estrogen alone may lower breast cancer risk while adding progestin seems to increase the risk is the million dollar question.

"There are hypotheses about the role of estrogen in breasts after a woman has gone through menopause," Anderson said. For example, "her breast tissue, including any precancerous cells, may go through changes as a result of menopause that make them susceptible to estrogen in a way that discourages cell growth."

Estrogen-only therapy is not without risks, however. For estrogen alone, the Women's Health Initiative data showed no overall effect of estrogen on heart disease, but an increased risk of strokes and blood clots.

Women are understandably confused about whether they should take hormones to treat their menopausal symptoms, and for how long they can safely use the therapy.

"The best use of estrogen-alone is in women with a hysterectomy who need relief of hot flashes and night sweats and related menopausal symptoms," Anderson said. These benefits need to be weighed against a woman's risk of stroke or developing blood clots.

Dr. Lila Nachtigall, a professor of obstetrics and gynecology at NYU Langone Medical Center in New York City, agreed that, when used on its own, estrogen can still be safe and effective in treating the symptoms of menopause in women who do not have a uterus.

"It looks very definite that the bad guy is progestin, not estrogen," Nachtigall said. Her advice is to use the lowest effective dose for the shortest amount of time. If more women took estrogen, she said, there would be a dent made in the epidemic of osteoporosis. "Millions of women who never went on estrogen, even for a few years, are really losing bone," she said.

That said, estrogen does increase the risk of blood clots. "Women with blood-clotting disorders should not take it," Nachtigall said.

Commenting on the study, Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, said, "If you are looking to reduce menopausal symptoms and don't have an intact uterus, [estrogen] is an option." But estrogen-only therapy should not be prescribed indiscriminately, she added.

"This applies only to women who have severe menopausal symptoms. We are not saying that we should give women estrogen to reduce the risk of breast cancer," Bernik added.

More information

Learn more about the benefits and risks of hormone replacement therapy through the North American Menopause Society.

SOURCES: Lila Nachtigall, M.D., professor, obstetrics and gynecology, NYU Langone Medical Center, New York City; Garnet Anderson, Ph.D., principal investigator, Women's Health Initiative Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle; Stephanie Bernik, M.D., chief, surgical oncology, Lenox Hill Hospital, New York City; March 7, 2012, The Lancet Oncology, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Estrogen-Only Hormone Therapy May Reduce Breast Cancer Risk for Some
2. Internet-based therapy relieves persistent tinnitus
3. New universal platform for cancer immunotherapy developed by Penn-led team
4. A culprit behind brain tumor resistance to therapy
5. How chemotherapy becomes more effective
6. New approach to stroke therapy
7. Researchers find sarcoma tumor immune response with combination therapy
8. Web-Based Therapy May Help Teens With Chronic Fatigue
9. Combination therapy may enhance gemcitabine activity
10. First study on long-term cognitive effects of breast cancer chemotherapy finds subtle impairment among women who received CMF regimen
11. Aurora-A hinders tumor-suppressor to allow chemotherapy resistance
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Estrogen-Only Therapy May Reduce Breast Cancer Risk
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has selected Dr. Nick ... in Rio. Under the care of Maximized Living doctors at the London Olympics ... showing, Maximized Living is sending the largest contingent of elite chiropractors to Rio to ...
(Date:4/29/2016)... ... 29, 2016 , ... Memorial Healthcare System Graduate Medical ... (ACGME) that it has received accreditation for its residency program on Physical Medicine ... that Memorial is currently pursuing, including Pediatrics and Internal Medicine. This accreditation allows ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie ... best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live ... thereafter . Dr. Bernie Siegel, author of a plethora of essential books-to-read ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a ... proud to announce one of their physicians has been invited to be a featured ... ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. Scott ...
(Date:4/29/2016)... ... ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of skin ... More than 10,000 people are expected to die of melanoma this year. The risk increases ... of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 2016  Hologic, Inc. (Nasdaq: HOLX ... the fiscal second quarter ended March 26, 2016.  ... increased 41.2%, and non-GAAP diluted EPS of $0.47 ... on a reported basis, and 6.3% on a ... another good quarter, highlighted by 14.6% growth in ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
(Date:4/27/2016)... 2016   Zillion Group today announced ... platform, which specializes in live video consultation. Turning ... products, Zillion enables companies to realize the true ... take control of their health. ... including one-to-one, group and webcast scheduled or on-demand ...
Breaking Medicine Technology: